Aktuellt
SENASTE
Redeye leaves a comment following the promising recent interim data from Faron’s BEXMAB study and interactions with regulatory authorities. We are encouraged to see that development continues to progress according to plan, with new data reaffirming earlier positive results, and that the potential of bexmarilimab is being recognized.
LÄS MER
